2026 Global: Artificial Pancreas Device System (Adps) Market-Competitive Review (2032) report
Description
The 2026 Global: Artificial Pancreas Device System (Adps) Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Medtronic, HQ: Dublin, Ireland, leads the artificial pancreas device system (ADPS) market with its MiniMed line and Guardian sensors, integrating insulin pumps and continuous glucose monitoring to produce reliable closed-loop performance. Tandem Diabetes Care, HQ: San Diego, United States, follows closely with the t:slim X2 pump and the Control‑IQ algorithm, automating titration using Dexcom CGM data and offering a streamlined experience for many patients. Insulet Corporation, HQ: Acton, Massachusetts, United States, focuses on tubeless Omnipod systems that now support automated dosing through Omnipod 5 when paired with Dexcom sensors, appealing to users seeking freedom from tubing and a simplified management routine. Dexcom, HQ: San Diego, United States, contributes essential telemetry through its CGM technology that many closed‑loop systems rely on for real‑time glucose information, enabling cross‑device interoperability and broader ADPS adoption. These brands collectively drive automation, patient satisfaction, and data sharing, shaping regulatory and reimbursement pathways for type 1 diabetes.
Abbott, HQ: Abbott Park, United States, remains a pivotal CGM supplier with FreeStyle Libre platforms that feed into multiple closed‑loop systems and influence ADPS adoption through data accessibility and sensor accuracy. Ypsomed, HQ: Burgdorf, Switzerland, offers the mylife open platform and pumps such as the mylife YpsoPump, enabling flexible integration with external controllers and CGMs for closed‑loop therapy across European markets. Diabeloop, HQ: Paris, France, develops the DBLG1 closed‑loop algorithm deployed with Dexcom CGMs and insulin pumps, progressing regulatory clearances and expanding into international clinics. Inreda Diabetic AB, HQ: Stockholm, Sweden, pursues an open approach to insulin delivery and automation through partnerships and pilot projects, aiming to bring patient‑centered closed‑loop solutions to Nordic healthcare systems. Abbott’s Libre sensors, including Libre 2, provide real‑time alarms and streaming data that enhance safety in closed‑loop use. Ypsomed emphasizes modular pump‑CGM integration across Europe, while Diabeloop pursues regulatory milestones and Inreda advances Nordic pilots.
Beta Bionics, HQ: Danvers, Massachusetts, United States, is developing the iLet automated insulin delivery system, a compact, battery‑powered device designed to operate with a range of CGMs and insulin therapies. The company pursues dual‑hormone and single‑hormone configurations to mimic physiological insulin action and glucagon rescue. In pivotal trials, iLet has demonstrated improved time in range for both pediatric and adult cohorts and has sought broader regulatory approvals in the United States and Europe. Cellnovo, HQ: London, United Kingdom, has pursued a patch‑pump based approach to ADPS, seeking to minimize device burden and maximize mobility for users. Its platform integrates wireless communication, automated dosing, and app‑based patient interfaces to support closed‑loop therapy. Together, these two firms illustrate the diversification within ADPS: from modular, pump‑and‑CGM ecosystems to compact, patchpump paradigms. As the market matures, partnerships and regulatory milestones will determine the pace at which their technologies reach everyday clinical care. worldwide adoption.
Medtronic, HQ: Dublin, Ireland, leads the artificial pancreas device system (ADPS) market with its MiniMed line and Guardian sensors, integrating insulin pumps and continuous glucose monitoring to produce reliable closed-loop performance. Tandem Diabetes Care, HQ: San Diego, United States, follows closely with the t:slim X2 pump and the Control‑IQ algorithm, automating titration using Dexcom CGM data and offering a streamlined experience for many patients. Insulet Corporation, HQ: Acton, Massachusetts, United States, focuses on tubeless Omnipod systems that now support automated dosing through Omnipod 5 when paired with Dexcom sensors, appealing to users seeking freedom from tubing and a simplified management routine. Dexcom, HQ: San Diego, United States, contributes essential telemetry through its CGM technology that many closed‑loop systems rely on for real‑time glucose information, enabling cross‑device interoperability and broader ADPS adoption. These brands collectively drive automation, patient satisfaction, and data sharing, shaping regulatory and reimbursement pathways for type 1 diabetes.
Abbott, HQ: Abbott Park, United States, remains a pivotal CGM supplier with FreeStyle Libre platforms that feed into multiple closed‑loop systems and influence ADPS adoption through data accessibility and sensor accuracy. Ypsomed, HQ: Burgdorf, Switzerland, offers the mylife open platform and pumps such as the mylife YpsoPump, enabling flexible integration with external controllers and CGMs for closed‑loop therapy across European markets. Diabeloop, HQ: Paris, France, develops the DBLG1 closed‑loop algorithm deployed with Dexcom CGMs and insulin pumps, progressing regulatory clearances and expanding into international clinics. Inreda Diabetic AB, HQ: Stockholm, Sweden, pursues an open approach to insulin delivery and automation through partnerships and pilot projects, aiming to bring patient‑centered closed‑loop solutions to Nordic healthcare systems. Abbott’s Libre sensors, including Libre 2, provide real‑time alarms and streaming data that enhance safety in closed‑loop use. Ypsomed emphasizes modular pump‑CGM integration across Europe, while Diabeloop pursues regulatory milestones and Inreda advances Nordic pilots.
Beta Bionics, HQ: Danvers, Massachusetts, United States, is developing the iLet automated insulin delivery system, a compact, battery‑powered device designed to operate with a range of CGMs and insulin therapies. The company pursues dual‑hormone and single‑hormone configurations to mimic physiological insulin action and glucagon rescue. In pivotal trials, iLet has demonstrated improved time in range for both pediatric and adult cohorts and has sought broader regulatory approvals in the United States and Europe. Cellnovo, HQ: London, United Kingdom, has pursued a patch‑pump based approach to ADPS, seeking to minimize device burden and maximize mobility for users. Its platform integrates wireless communication, automated dosing, and app‑based patient interfaces to support closed‑loop therapy. Together, these two firms illustrate the diversification within ADPS: from modular, pump‑and‑CGM ecosystems to compact, patchpump paradigms. As the market matures, partnerships and regulatory milestones will determine the pace at which their technologies reach everyday clinical care. worldwide adoption.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
